2022
DOI: 10.21203/rs.3.rs-2114958/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Abstract: Background Neoadjuvant concurrent chemoradiotherapy with surgery was the standard of therapy for esophageal cancer. But many patients refused or abandoned radiotherapy because of the intolerable adverse effects in China. Neoadjuvant immunochemotherapy (nICT) followed by surgery has become an emerging treatment in patients with esophageal cancer. There was still no consensus on whether neoadjuvant immunochemotherapy was superior to neoadjuvant chemotherapy (nCT) alone in patients with esophageal cancer. Metho… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 27 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?